Abstract
Nonsteroidal anti-inflammatory drugs (NSAIDs) have shown promise in colorectal cancer (CRC), but they are compromised by gastrotoxicity. NO-NSAIDs are hybrid nitrates conjugated to an NSAID designed to exploit the gastroprotective properties of NO bioactivity. The NO chimera ethyl 2-((2,3-bis(nitrooxy)propyl)disulfanyl)benzoate (GT-094), a novel nitrate containing an NSAID and disulfide pharmacophores, is effective in vivo in rat models of CRC and is a lead compound for design of agents of use in CRC. Preferred chemopreventive agents possess 1) antiproliferative and 2) anti-inflammatory actions and 3) the ability to induce cytoprotective phase 2 enzymes. To determine the contribution of each pharmacophore to the biological activity of GT-094, these three biological activities were studied in vitro in compounds that deconstructed the structural elements of the lead GT-094. The anti-inflammatory and antiproliferative actions of GT-094 in vivo were recapitulated in vitro, and GT-094 was seen to induce phase 2 enzymes via the antioxidant responsive element. In the variety of colon, macrophage-like, and liver cell lines studied, the evidence from structure-activity relationships was that the disulfide structural element of GT-094 is the dominant contributor in vitro to the anti-inflammatory activity, antiproliferation, and enzyme induction. The results provide a direction for lead compound refinement. The evidence for a contribution from the NO mimetic activity of nitrates in vitro was equivocal, and combinations of nitrates with acetylsalicylic acid were inactive.
Footnotes
-
This research was funded in part by National Institutes of Health grants CA102590 and CA121107.
-
ABBREVIATIONS: CRC, colorectal cancer; ACF, aberrant crypt foci; AOM, azoxymethane; iNOS, inducible nitric-oxide synthase; NSAID nonsteroidal anti-inflammatory drug; ASA, aspirin; GI, gastrointestinal; NO-NSAID, NO-donating nonsteroidal anti-inflammatory drug; BECS, 1,2-bis-(2-ethoxycarbonylphenyl)sulfane; FBS, fetal bovine serum; DMEM, Dulbecco's modified Eagle's medium; ARE, antioxidant responsive element; LPS, lipopolysaccharide; l-NAME, Nω-nitro-l-arginine methyl ester; CM, conditioned media; PBS, phosphate buffered saline; ERK, extracellular signal-regulated kinase; ERK, extracellular signal-regulated kinase; NQO1, NAD(P)H-dependent quinone oxidoreductase; CI, chemopreventive index; RT-PCR, reverse transcription-polymerase chain reaction; TNF, tumor necrosis factor; IL, interleukin; COX, cyclooxygenase; PG, prostaglandin; SPE/NO, spermine diazeniumdiolate salt; DETA/NO, diethyltriamine diazeniumdiolate; BF, 4′-bromoflavone; ISDN, isosorbide dinitrate; PTIO, 2-phenyl-4,4,5,5-tetramethylimidazoline-l-oxyl-3-oxide; CD, concentration required to double the specific activity of NAD(P)H-dependent quinone oxidoreductase; ODQ, 1H-[1,2,4]oxadiazolo[3,4-a]quinoxalin-1-one; MAPK, mitogen-activated protein kinase; PD 98059, 2′-amino-3′-methoxyflavone; GTN, nitroglycerin; DADS, dipropyl disulfide and diallyl disulfide; Keap1, protein Kelch-like ECH-associated protein 1; NCX 4016, 2-acetoxybenzoate-2-(1-nitroxymethyl)phenyl ester; GT-947, ethyl 2-(1,3-bis(nitrooxy)propan-2-ylthio)benzoate; GT-794, ethyl 2-(2,3-bis(nitrooxy)propylthio)benzoate; GT-103, 2-((2,3-bis(nitrooxy)propylthio)carbonyl)phenyl acetate; GT-094, ethyl 2-((2,3-bis(nitrooxy)propyl)-disulfanyl)benzoate; GT-015, 3,3′-disulfanediylbis(propane-3,2,1-triyl) tetranitrate.
-
↵
The online version of this article (available at http://molpharm.aspetjournals.org) contains supplemental material.
- Received February 23, 2008.
- Accepted August 1, 2008.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|